Announcements Trials
Browse Landscape

Phase

Phase 3 8Phase 2 5Phase 1 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 5INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 4Breast 1

Conditions

Small Cell Lung Carcinoma 4Breast Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × amrubicin × Clear all
NCT01904253 2024-09-05

A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

Taiho Oncology, Inc.

Phase 2 Terminated
18 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT00388960 2019-11-19

Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

Celgene

Phase 2 Completed
99 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT00375193 2019-10-24

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

Celgene

Phase 2 Completed
75 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT00319969 2009-09-30

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

Celgene

Phase 2 Completed
76 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT00380835 2008-09-23

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

Celgene

Phase 2 Withdrawn
66 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡